Role of Exercise in Depression in Middle Aged and Older Adults
NCT ID: NCT01573728
Last Updated: 2016-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2012-05-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This pilot is a three-arm design of low dose exercise versus public health dose exercise intended to: 1) establish the feasibility, acceptance, and safety of Internet-based supervised exercise training and 2) obtain retention and attendance estimates needed to determine sample sizes for the follow-up trial.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physical Exercise and Depressive Symptoms in Moderately or Severely Depressed Adults
NCT05703776
Aerobic Exercise as add-on Treatment for Inpatients With Depression
NCT02679053
Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly
NCT00931814
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
NCT00695552
Dose-Response Effect Exercise and Depression
NCT06166095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following recruitment by the PBRN, study personnel will call and confirm the PHQ-9 results with the SCID. If the patient passes the follow-up screening, the staff will arrange to travel to the patient's home. Study staff will obtain informed consent and perform baseline assessments including the Short Form-36, PHQ-9, Generalized Anxiety Disorder-7 (GAD-7), Medical Outcomes Study Social Support survey, and the ASA 24. The ASA 24 is an online dietary screener that measures energy intake over a 24 hour period. It is posted on the National Cancer Institute's website. Medication adherence and smoking levels will be measured by self report. Height, weight, waist circumference, and blood pressure will also be measured. With the exception of the SCID, each of these measures will be repeated at 3 month follow-up. The PHQ-9 will be completed monthly. Also, each month (three different time periods) participants will be asked to wear an armband accelerometer to measure energy expenditure over a 2 week period. The protocol gives details of the accelerometry procedures.
Blood will be drawn using a 2 ten ml tubes at base line and 3 month follow-up using procedures described in the Data Safety and Monitoring Plan. We will ask that the participants fast for eight hours prior to the blood draw, but will note if that was not possible. Appointments for the blood draw will be made within five days of the assessment and also take place within the participant's home.. The blood samples will measure circulating levels of the proinflammatory cytokines IL-1α, IL-1β, IL-6, and TNF-α; the anti-inflammatory cytokines IL-1ra and IL-10; the acute-phase reactant CRP; and VEGF and BDNF.
Participants will be randomized to public health or low dose exercise. Randomization will be stratified by baseline use/no use of prescription anti-depressants. Both low and public health exercise arms will receive supervised one on one instruction via video conference. The exercise will occur five times a week for 10 to 30 minutes each session. During the twelve week intervention, the exercise will increase in intensity and may include wrist and ankle weights. During each session, the participant will rate their perceived exertion using the Borg's Rating of Perceived Physical Exertion (RPE): a 10 Point Scale where 0 is no movement and 10 is maximum effort. Participants will also wear a heart rate monitor. Participants in the low dose exercise arm will be instructed to exercise at an RPE of less than 5 and a heart rate of less than 50% of their age-adjusted maximum (200 minus participant's age). The participants in the public health dose arm will be instructed to exercise at an RPE of between 5 and 7 and to maintain a heart rate of 55 to 70% of age-adjusted maximum heart rate.
All assessments and blood draws will occur in the participant's home.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Exercise Arm
Low dose exercise (50 Minutes)
Low dose exercise
Exercise totaling 50 minutes per week and low intensity
Public Health Exercise
Public Health dose exercise (150 minutes)
Public Health Exercise
At least 150 minutes at moderate intensity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose exercise
Exercise totaling 50 minutes per week and low intensity
Public Health Exercise
At least 150 minutes at moderate intensity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
46 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Clark
Associate Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel O Clark, PhD
Role: PRINCIPAL_INVESTIGATOR
Indiana University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University School of Medicine
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1111007450
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.